Although substantial emphasis is placed on vaccinations in considering how to limit the spread of influenza, simple hygienic methods have been found to be the most effective and should be more widely supported.
Adults who received the flu vaccine in 2017 to 2018 had higher antibody titers against the egg-adapted vaccine and lower titers against circulating virus.
The Food and Drug Administration has accepted for review the supplemental New Drug Application (sNDA) for Xofluza (baloxavir marboxil; Genentech) for the treatment of influenza in patients at high risk of complications.
Tafenoquine has performed comparably with primaquine in terms of hemoglobin level decrease in individuals with malaria and normal glucose-6-phosphate dehydrogenase enzyme levels.
In pediatric patients aged 2-17 years, the live attenuated vaccine was less effective against influenza A/H1N1pdm09 compared with the inactivated vaccine.
